BOPI 03 BR / 2025 REPERTOIRE NUMERIQUE 13 Fig. 1 ________________________________________ (11) 21830 Consulter le mémoire (51) A61K 31/429 (2018.01); A61K 31/506 (2018.01) ; G01N 33/68 (2018.01) (21) 1202300363 - PCT/US2022/019513 (22) 09/03/2022 (30) US n° 63/159,271 du 10/03/2021; US n° 63/226, 551 du 28/07/2021; US n° 63/234, 487 du 18/08/2021; US n° 63/292, 815 du 22/12/2021 et US n° 63/308, 790 du 10/02/2022 (54) Small molecule inhibitors of mammalian SLC6A19 function. (72) BROWN, Dean, G. (US); HENDERSON, Jaclyn, L. (US); MUNCIPINTO, Giovanni (US); ZWEIG, Joshua, E. (US); NGUYEN, Long, V. (US); PULLEN, Nicholas (US); ANTALEK, Mitchell, T. (US) et HOLLIBAUGH, Ryan, A. (US) (73) Jnana Therapeutics Inc., 6 Tide Street, BOSTON, MA 02210 (US) (74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, The House of Gideon, Golf/Bastos Quater, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.
RkJQdWJsaXNoZXIy MTM1NDc3MA==